Tag: in-licensing

April 3, 2018

Mustang Bio Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights

Mustang Bio (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen...
February 27, 2018

Amarin Reports Record Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Operations

Amarin Corporation (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial...
February 22, 2018

Glance Announces White Label Blockchain Solution

Glance Technologies (CSE:GET) has announced that it is pursuing opportunities to license its recently acquired BlockImpact cryptocurrency and blockchain platform...
February 16, 2018

Amicus Therapeutics Prices Underwritten Offering of Common Stock

Amicus Therapeutics (Nasdaq:FOLD) announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share....
February 15, 2018

Amicus Therapeutics Announces Public Offering of Common Stock

Amicus Therapeutics (Nasdaq:FOLD) announced it has commenced a $250 million underwritten public offering of its common stock. J.P. Morgan Securities...
January 26, 2018

Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock

Stemline Therapeutics (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the closing of a previously announced underwritten public...
January 22, 2018

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

Stemline Therapeutics (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it intends to offer and sell,...